RT Journal Article
SR Electronic
T1 Relationship between LAT1 Expression and Response to Platinum-based Chemotherapy in Non-small Cell Lung Cancer Patients with Postoperative Recurrence
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3775
OP 3782
VO 31
IS 11
A1 KYOICHI KAIRA
A1 TOSHIAKI TAKAHASHI
A1 HARUYASU MURAKAMI
A1 TAKEHITO SHUKUYA
A1 HIROTSUGU KENMOTSU
A1 TATEAKI NAITO
A1 NOBORU ORIUCHI
A1 YOSHIKATSU KANAI
A1 MASAHIRO ENDO
A1 HARUHIKO KONDO
A1 TAKASHI NAKAJIMA
A1 NOBUYUKI YAMAMOTO
YR 2011
UL http://ar.iiarjournals.org/content/31/11/3775.abstract
AB Background: The aim of this study was to investigate whether L-type amino acid transporter 1 (LAT1) expression can predict poor outcome after chemotherapy in patients with non-small cell lung cancer (NSCLC). Materials and Methods: Immunohistochemistry was carried out to examine the expression of LAT1, CD98, vascular endothelial growth factor (VEGF), Ki-67, phosphorylation of Akt (p-Akt), phosphorylation of mammalian target of rapamycin (p-mTOR) and p53 in resected lung tumor specimens obtained from 56 patients treated with platinum-based chemotherapy. Results: Positive LAT1 and CD98 expression was recognized in 45% (25/56) and 34% (19/56), respectively. In NSCLC (N=56), LAT1, CD98, VEGF, Ki-67 and p53 were significant factors for predicting poor outcome, and adenocarcinoma was an independent factor for predicting favorable prognosis. LAT1 expression was closely associated with chemoresistance. In adenocarcinoma (N=37), a statistically significant inverse relationship was observed between the expression of LAT1, VEGF and Ki-67 and epidermal growth factor receptor (EGFR) mutation, and positive expression of LAT1 and VEGF was an independent factor for predicting poor prognosis after chemotherapy. Conclusion: LAT1 expression may be useful for predicting response and outcome after systemic chemotherapy.